Immuno-therapy (ITH)

UIIS ITH Committee Introduction

Mandate
Assist in the development and clinical application of immunotherapy in the treatment of cancer and infectious diseases with special emphasis on the developing world. Remit includes:

1) Develop policy positions on the application of new immune therapy approaches in cancer and infectious diseases.
2) Communication with other organizations devoted the supporting immunotherapy (i.e. SITC; joint projects);
3) Sponsor public and academic education on immune therapy issues (i.e. travel fellowships to SITC meetings; course planned for 2016/2017)
Committee Successes

1) Organized committee (will include others)
2) Developed links to other immunotherapy organizations
3) Discussions have lead to a proposed mandate for the ITH Committee

- The IUIS is coming late into the field with many organizations having already established with a foot-hold in immunotherapy. We should avoid overlap and instead develop a **complementary role**.
- From discussions with other organizations, we can help as an information source and coordinator of activities linked to immunotherapy, but with an emphasis on **education** and the application of immunotherapy to the **developing world**.
- Given that the huge focus of new immunotherapies is on cancer, we need to be part of this exciting activity. I believe that we can best participate by promoting the **application of these new therapeutic strategies in cancer to infectious diseases**.
- We can develop policy positions (Frontiers in Immunology), and and propose the most **cost effective options for the developing world**.
- **Organize education courses** in immunotherapy in the developing world.
- **Have established contacts** and potential collaborators so far have included the American Cancer Society, Cancer Research Institute (CRI), Cancer Research UK (CRUK), and Society for Immunotherapy of Cancer (SITC). Others see Addendum.
Cancer Immunotherapy Course (2016/17) (initial focus on cancer)
(Proposed teachers: Rudd, Bartůňková, Boyer, June and others)
Venue: (India, Africa?)

Topics:
Basic Immunology
Biomarkers
Cancer Immunology: Immunology, Inflammation and Tumor Growth
New Immune Checkpoint Inhibitors
Virus Therapy in Cancer Immunotherapy
Cellular Therapies
Vaccination and immunotherapy

Provide travel fellowships for students to attend immunotherapy meetings (SITC)

Develop policy statements related to cancer (most cost effective) and the application of new approaches in cancer to the treatment of infectious diseases.

Need funding (proposed initially $10K)
Addendum

World Immunotherapy Council (WIC)

Other Possible Participating Organizations
Adoptive Engineered T cell Targeting toActivate Cancer Killing (ATTACK)
Australian Working Group
Canadian Cancer Immunotherapy Consortium (CCIC)
Cancer Drug Development Forum (CDDF)
Cancer Immunotherapy Consortium - Cancer Research Institute (CIC-CRI)
Association for Cancer Immunotherapy (CIMT)
Cancer Research Institute (CRI)
Chinese Society of Clinical Oncology (CSCO)
Dutch Tumor Immunology Working Party (DTIWP)
European Academy of Tumor Immunology (EATI)
European Society of Cancer Immunology and Immunotherapy (ESCII)
German Cancer Immunology group in the German Immunology Society (DGFI)
Japanese Association of Cancer Immunotherapy (JACI)
Middle Eastern and North African Interest Group
Italian Network for Tumor Biotherapy (NIBIT)
National Institute of Oncology, Budapest
Progress In Vaccination Against Cancer (PIVAC)
Scandinavian Network for Immunotherapy of Cancer (SNIC)
Society for Immunotherapy of Cancer (SITC)
Committee for Tumor Immunology and Bio-Therapy (TIBT)
Tumor Immunology Meets Oncology (TIMO)
Tumor Vaccine and Cell Therapy Working Group (TVACT)